Skip to content

D&A at other companies

Amgen logo
AmgenAMGN

Segments

By segment

See full
Biopharm Division$130K+31.3%
Neurostimulation Division$13K-56.7%

Other financials

Income statement

See full
Revenue-
Gross profit$130.0K
Operating income-$6.8M-4.0%
Net income-$6.8M-7.6%
EPS (diluted)-$0.08+27.3%

Balance sheet

See full
Cash & equivalents$19.0M+57.7%
Total debt$18.3M-3.5%
Total equity$19.1M+64.2%
Total assets$42.4M+19.5%

Cash flow

See full
Operating cash flow-$6.2M-20.0%
CapEx$3.0K-40.0%
Free cash flow-$6.2M-19.9%

Valuation

See full
Market cap$106.93M+40.0%
Enterprise value$106.17M+19.3%

Profitability

See full
Gross margin36.3%
Operating margin-1,004.9%
Net margin-994.1%
FCF margin-832.3%

Returns & leverage

See full
Return on equity-176.4%+175pp
Debt / equity-0.7×
Current ratio3.2×+0.8×

Where this comes from

Reported directly by Vivani Medical in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Vivani Medical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vivani Medical's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vivani Medical's D&A?
Vivani Medical (VANI) reported D&A of $130K in Q1 2026.
How has Vivani Medical's D&A changed year-over-year?
Vivani Medical's D&A increased by 27.5% year-over-year, from $102K to $130K.
What is the long-term trend for Vivani Medical's D&A?
Over 4 years (2021 to 2025), Vivani Medical's D&A has grown at a 5.3% compound annual growth rate (CAGR), from $345K to $424K.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.